Holen Sie sich die Stockscreener-App
26.34
3.57%
1.00
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
PHVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
How Pharvaris N.v. (PHVS) Affects Rotational Strategy Timing - Stock Traders Daily
PHVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Lancet publishes Phase 2 oral treatment data for rare swelling disorder - Stock Titan
Guggenheim maintains Pharvaris NV (PHVS) buy recommendation - MSN
[Form 3] Pharvaris N.V. Initial Statement of Beneficial Ownership - Stock Titan
Pharvaris (PHVS) director Glassman reports stock options and RSU holdings - Stock Titan
Pharvaris (PHVS) director discloses sizable stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) director details options, RSUs and shares - Stock Titan
Pharvaris (PHVS) CFO discloses common stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) CTO reports option grants and share holdings - Stock Titan
Pharvaris (PHVS) CCO reports initial stock, RSU and option holdings - Stock Titan
Pharvaris (PHVS) PAO reports initial share, option and RSU holdings - Stock Titan
Pharvaris (PHVS) director David Meeker reports stock, options and RSUs - Stock Titan
Pharvaris (PHVS) director Viviane Monges details initial equity holdings - Stock Titan
Pharvaris (PHVS) CMO Lu Peng details initial share and stock option holdings - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig details stock, RSUs and options - Stock Titan
Pharvaris (PHVS) CHRO details option and RSU equity holdings - Stock Titan
Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)? - simplywall.st
Trend Recap: How sensitive is Pharvaris NV to inflation2026 Risk Factors & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After New Real‑World HAE Study Supports Deucrictibant Trials - Sahm
Patient attack ratings to guide Pharvaris hereditary angioedema trials - Stock Titan
PHVS: Oral therapies for angioedema show strong data, with launches and key filings expected by 2027 - TradingView
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Royal Bank Of Canada - Defense World
Can Pharvaris (PHVS) Turn Deucrictibant’s Phase 2 Extension Data Into a Durable Franchise Advantage? - simplywall.st
(PHVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
PHVS Should I Buy - Intellectia AI
Pharvaris N.V. (PHVS) Presents at American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual MeetingSlideshow (NASDAQ:PHVS) 2026-03-05 - Seeking Alpha
Portfolio Recap: Does Pharvaris NV stock have upside surprise potentialQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Movement Recap: How correlated is Pharvaris NV to the S P500July 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Promising 65.84% Potential Upside in Biotech - DirectorsTalk Interviews
Responsive Playbooks and the PHVS Inflection - Stock Traders Daily
PHVS: Oral HAE therapy shows strong phase III results, with NDA filing and key data expected this year - TradingView
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Pharvaris shares slide following $175 million equity offering - MSN
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm
Bain Capital Life Sciences shows 4.3% Pharvaris (PHVS) ownership in Schedule 13G/A - Stock Titan
Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily
PHVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Shorts: What is the Moat Score of Pharvaris N.V.2025 Buyback Activity & Smart Swing Trading Techniques - mfd.ru
Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside Of 75% In The Biotech Sector - DirectorsTalk Interviews
Does Pharvaris N.V. stock have upside surprise potentialIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
Will Pharvaris N.V. stock gain from lower inflationEarnings Summary Report & Accurate Trade Setup Notifications - mfd.ru
Will Pharvaris N.V. stock recover faster than peersQuarterly Portfolio Review & Comprehensive Market Scan Insights - mfd.ru
Aug Swings: How sensitive is Pharvaris NV to inflationQuarterly Investment Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Oral drug for hereditary angioedema attacks shows Phase 3 data at AAAAI 2026 - Stock Titan
Aug Outlook: Is Pharvaris NV stock a value trapJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Aug Gainers: Can Pharvaris NV stock outperform in a bear marketJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
The Technical Signals Behind (PHVS) That Institutions Follow - Stock Traders Daily
Pharvaris Rings the Opening Bell - Nasdaq
Pharvaris Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Pharvaris N.V. (PHVS) Stock Analysis: A Biotechnology Gem With 69% Upside Potential - DirectorsTalk Interviews
What’s the fair value of Pharvaris N.V. stockPortfolio Return Summary & Expert Verified Movement Alerts - mfd.ru
Meme Stocks: Is NextNav Inc Equity Warrant exposed to currency risksPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Analysts Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $40.56 - Defense World
Precision Trading with Pharvaris N.v. (PHVS) Risk Zones - Stock Traders Daily
2.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):